Effects of a Lactobacillus salivarius probiotic intervention on infection, cold symptom duration and severity, and mucosal immunity in endurance athletes by Michael Gleeson (7239578) et al.
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
235
International Journal of Sport Nutrition and Exercise Metabolism, 2012, 22, 235 -242 
© 2012 Human Kinetics, Inc.
Gleeson, Bishop, Oliveira, and McCauley are with the School of 
Sport, Exercise and Health Sciences, Loughborough University, 
Loughborough, UK. Tauler is with the Dept. of Fundamental 
Biology and Health Sciences, University of the Balearic Islands, 
Palma de Mallorca, Spain. Lawrence is with GlaxoSmithKline 
Nutrition, Brentford, UK.
Effects of a Lactobacillus salivarius Probiotic Intervention 
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The purpose of this study was to examine the effects of a probiotic supplement during 4 mo of spring training 
in men and women engaged in endurance-based physical activities on incidence of upper respiratory tract 
infections (URTI) and mucosal immune markers. Sixty-six highly active individuals were randomized to 
probiotic (n = 33) or placebo (n = 33) groups and, under double-blind procedures, received probiotic (PRO: 
Lactobacillus salivarius, 2 × 1010 bacterium colony-forming units) or placebo (PLA) daily for 16 wk. Resting 
blood and saliva samples were collected at baseline and after 8 and 16 wk. Weekly training and illness logs 
were kept. Fifty-four subjects completed the study (n = 27 PRO, n = 27 PLA). The proportion of subjects on 
PRO who experienced 1 or more wk with URTI symptoms was not different from that of those on PLA (PRO 
.58, PLA .59; p = .947). The number of URTI episodes was similar in the 2 groups (PRO 1.6 ± 0.3, PLA 1.4 ± 
0.3; p = .710). Severity and duration of symptoms were not significantly different between treatments. Blood 
leukocyte, neutrophil, monocyte, and lymphocyte counts; saliva IgA; and lysozyme concentrations did not 
change over the course of the study and were not different on PRO compared with PLA. Regular ingestion 
of L. salivarius does not appear to be beneficial in reducing the frequency of URTI in an athletic cohort and 
does not affect blood leukocyte counts or levels of salivary antimicrobial proteins during a spring period of 
training and competition.
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Original research
Probiotics are food supplements containing live 
microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host. There is 
now a reasonable body of evidence that regular consump-
tion of probiotics can modify the population of the gut 
microbiota and influence immune function (Borchers, 
Selmi, Meyers, Keen, & Gershwin, 2009; Gill & Cross, 
2002; Matsuzaki, 1998; Mengheri, 2008; Minocha, 
2009), although it should be noted that such effects are 
strain specific. Some studies are suggestive of increased 
resistance to enteric pathogens and promotion of antitu-
mor activity with probiotic supplementation, and there 
is emerging evidence that probiotics may be effective 
in alleviating some allergic and respiratory disorders in 
children (Hatakka et al., 2001; Kopp-Hoolihan, 2001). 
Furthermore, it has been reported that probiotic supple-
mentation enhances host resistance to upper respiratory 
tract infection (URTI) in the general population (Berg-
gren, Lazou Ahrén, Larsson & Önning, 2011; de Vrese 
et al., 2006), and several recent studies have indicated 
that some Lactobacillus probiotics can reduce URTI 
incidence in athletes (Cox, Pyne, Saunders, & Fricker, 
2010; Gleeson, Bishop, Oliveira, & Tauler, 2011; West 
et al., 2011), who are generally considered a marginally 
immunocompromised population due to the depressive 
effects of hard physical exercise, psychological stress, 
sleep disturbance, and negative energy balance on the 
immune system (Gleeson, 2007; Walsh, Gleeson, Pyne, 
et al., 2011).
Reduced levels of salivary antimicrobial proteins 
(e.g., immunoglobulin A and lysozyme) in athletes may 
contribute to their increased risk of URTI (Fahlman & 
Engels, 2005; Gleeson et al., 2012; Gleeson et al., 1999; 
Neville, Gleeson & Folland, 2008; Walsh, Gleeson, 
Shephard, et al., 2011; West et al., 2010). The number 
of circulating leukocytes or specific lymphocyte subsets 
such as T-cytotoxic lymphocytes and natural killer (NK) 
cells might also influence susceptibility to viral infections 
such as URTI (Walsh, Gleeson, Shephard,  et al., 2011).
The aims of the current study were to examine 
the effects of 4 months of daily oral supplementation 
with a probiotic containing the gram-positive bacte-
ria Lactobacillus salivarius on infection incidence, 
salivary antimicrobial proteins, and blood leukocyte and 
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lymphocyte subset counts in a cohort of university-based 
endurance athletes during a period of spring training and 
competition.
Methods
Subjects
Sixty-six healthy subjects who were engaged in regular 
sports training (predominantly endurance-based activi-
ties such as running, cycling, swimming, triathlon, team 
games, and racket sports) volunteered to participate in 
the study. Subjects ranged from recreationally active 
to Olympic triathletes, and their self-reported training 
loads (based on the answer to the question “On average 
how many hours in each week do you train/compete?”) 
averaged 9 hr/week. Subjects were required to complete 
a comprehensive health-screening questionnaire before 
starting the study and had not taken any medication in 
the 4 weeks before the study. All subjects recruited to the 
study confirmed that they had not taken any probiotic in 
the previous 4 months. All subjects were fully informed 
about the rationale for the study and of all experimental 
procedures to be undertaken. They provided written 
consent to participate in the study, which had earlier 
received the approval of Loughborough University ethical 
advisory committee. Subjects were enrolled if they met 
all inclusion criteria and presented none of the exclusion 
criteria (determined by both questionnaire and interview).
Subjects could be included if they were currently 
healthy, had been involved in endurance training for at 
least 2 years, engaged in at least three sessions and at least 
3 hr of total moderate- to high-intensity training time per 
week, and were 18–35 years of age. Subjects representing 
one or more of the following criteria were excluded from 
participation: smoking; use of any medication; currently 
taking probiotic supplements; suffered from or had a his-
tory of cardiac, hepatic, renal, pulmonary, neurological, 
gastrointestinal, hematological, or psychiatric illness; 
objected to the prescription of diet (abstinence from fer-
mented milk products and other probiotic supplements).
A total of 66 healthy individuals were recruited as 
subjects and randomly assigned to one of two treatments 
with stratification by gender only; under double-blind 
procedures, 33 subjects received the probiotic and 33 
received the placebo preparation. Of these 66 subjects, 38 
were women and 28 were men, with the mean age of the 
study cohort at recruitment being 23.9 ± 4.7 years (M ± 
SD). Sample-size estimation of 32 subjects per treatment 
group was based on an expected rate of 2.0 ± 1.0 URTI 
episodes (M ± SD) during the winter months (Neville et 
al., 2008; Gleeson et al., 2011), a target 30% reduction 
in number of episodes, statistical power of 80%, and a 
Type I error of 5%.
First Laboratory Visit
The study began in the month of February. For the first 
visit to the laboratory, subjects arrived in the morning 
between 8:30 and 10:30 a.m. after an overnight fast of 
approximately 12 hr. They were asked to empty their 
bladder before body mass and height were recorded. 
Information about the study was given to them, and 
they then signed an informed-consent form. Subjects 
then sat quietly for 10 min and completed a health-
screen questionnaire and inclusion/exclusion-criteria 
questionnaire before providing an unstimulated saliva 
sample by passive dribble for 2 min into a preweighed 
sterile collection tube. Saliva samples were weighed and 
stored frozen at –80 °C before analysis. Subsequently, 
a resting venous blood sample (11 ml) was obtained 
by venipuncture from an antecubital forearm vein into 
two Vacutainer tubes (Becton Dickinson, Oxford, UK) 
containing either K3EDTA or heparin. Hematological 
analysis was immediately carried out on the EDTA 
sample (including hemoglobin, hematocrit, and total 
and differential leukocyte counts) using an automated 
cell counter (Ac.T5diff hematology analyzer, Beckman 
Coulter, High Wycombe, UK). If subjects met the criteria 
for inclusion of the study, they were randomly assigned to 
the treatment or placebo group and asked to start taking 
the supplement the next day.
Study Intervention
The L. salivarius probiotic and placebo treatments were 
supplied in the form of 2 g powder in a sealed aluminum 
sachet, which was to be opened and the contents added to 
a glass of water (50–100 ml) as part of a meal at breakfast 
time and consumed within 15 min of preparation on a 
daily basis for the 4-month intervention period. The probi-
otic supplement contained 0.2 g of L. salivarius (2 × 1010 
bacterium colony-forming units) with 1.78 g maltodextrin 
and 0.01 g magnesium stearate. The placebo contained 
the same amount of chemical vehicle (maltodextrin and 
magnesium stearate) as the probiotic but did not contain 
any bacteria. The probiotic and placebo supplements 
were stored at approximately 4–7 °C (domestic refrigera-
tor). Subjects returned to the laboratory every 4 weeks 
to receive a fresh supply of supplement. A compliance 
log of sample collection was taken. Subjects were asked 
to keep a record of any days that they missed taking the 
supplement.
Study Protocol
During the 4-month intervention period with probiotic 
(PRO) or placebo (PLA), subjects were asked to continue 
with their normal training programs. Consumption of 
supplements (vitamins and minerals, etc.), additional 
probiotics, or any fermented dairy products (e.g., yogurt, 
sour cream, crème fraîche) was not permitted during this 
period. Subjects completed a health (URTI symptoms) 
questionnaire on a weekly basis. They were not required 
to abstain from medication when they were suffering from 
illness symptoms, but they were required, on a weekly 
basis, to report any unprescribed medications taken, visits 
to the doctor, and any prescribed medications.
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The illness symptoms listed on the questionnaire 
were sore throat, catarrh (excessive mucus) in the throat, 
runny nose, cough, repetitive sneezing, fever, joint aches 
and pains, weakness, headache, and loss of sleep. The 
nonnumerical ratings of light, moderate, or severe (L, M, 
or S, respectively) of severity of symptoms were scored 
as 1, 2, or 3, respectively, to provide a quantitative means 
of data analysis (Fricker et al., 2005; Gleeson et al., 2012; 
Gleeson et al., 2011), and the total symptom score for 
every subject each week was calculated by multiplying 
the total number of days each symptom was experienced 
by the numerical ratings of L, M, or S symptoms of 1, 
2, or 3, respectively. In any given week, a total symptom 
score ≥12 was taken to indicate that a URTI was present. 
This score was chosen because to achieve it a subject 
would have to record at least three moderate symptoms 
lasting for 2 days or two moderate symptoms lasting for 
at least 3 days in a given week. A single URTI episode 
was defined as a period during which the weekly total 
symptom score was ≥12 and separated by at least 1 
week from another week with a total symptom score 
≥12. Subjects were also asked to rate the impact of ill-
ness symptoms on their ability to train (normal training 
maintained, training reduced, or training discontinued; 
L, M, or S, respectively).
Subjects were also asked to fill in a standard short 
form International Physical Activity Questionnaire 
(IPAQ; http://www.ipaq.ki.se/downloads.htm) at weekly 
intervals, thus providing quantitative information on 
training loads in metabolic equivalent (MET)-hr/week 
(Craig et al., 2003).
After 8 and 16 weeks, subjects came to the labora-
tory again after an overnight fast. They were required to 
abstain from any strenuous physical activity for 24 hr 
before coming to the laboratory to avoid acute effects 
of exercise on the measured blood and saliva variables. 
During these visits body mass was recorded and an 
unstimulated saliva sample and venous blood samples 
were collected as described for the first visit to the 
laboratory.
Blood Cell Counts  
and Lymphocyte Subsets
Blood samples in the K3EDTA Vacutainers (4 ml) were 
used for hematological analysis with an automated cell 
counter (Ac.T5diff hematology analyzer, Beckman Coul-
ter, High Wycombe, UK). The intra-assay coefficient of 
variation for all measured variables was less than 3.0%.
Lymphocyte subsets (CD3, CD4, CD8, CD19, CD56) 
to enumerate total T cells, T-helper cells, T-cytotoxic 
cells, B cells, and NK cells were determined by three-
color flow cytometry (Becton Dickinson FACS-Calibur) 
with CellQuest analysis software (Becton Dickinson 
Biosciences, Oxford, UK) as described previously (Lan-
caster et al., 2004). Forward-scatter versus side-scatter 
plots were used to gate on the lymphocyte population 
by morphology, and 10,000 lymphocyte events were 
acquired per analysis. Estimations of the absolute CD3+, 
CD3+CD4+, CD3+CD8+, NK cell (CD3-CD56+), and B 
cell (CD3-CD19+) numbers were derived from the total 
lymphocyte count.
Saliva IgA and Lysozyme
Saliva was analyzed for immunoglobulin A (IgA) using an 
ELISA kit (Salimetrics, USA) and for lysozyme using an 
ELISA kit (Biomedical Technologies, Stoughton, MA). 
For both assays, saliva samples were assayed in duplicate, 
standards (also in duplicate) were included on every plate, 
and samples for each subject were analyzed on the same 
plate. The intra-assay coefficients of variation for IgA 
and lysozyme were 10.1% and 5.0%, respectively. Saliva 
flow rates (ml/min) were determined from the weight of 
saliva collected, assuming saliva density to be 1.0 g/ml 
(Cole & Eastoe, 1988), divided by the collection time. 
Secretion rates for IgA and lysozyme were calculated by 
multiplying their respective concentrations in saliva by 
the saliva flow rate.
Statistical Analysis
The difference in proportion of subjects who presented 
with symptoms of infection during the trial between the 
PRO and PLA groups was assessed by a chi-square test. 
Comparisons of the proportion of days or weeks with 
infection symptoms were also made with a chi-square 
test. For subjects with infection symptoms, the total 
symptom-severity score and the mean duration of infec-
tion symptoms, comparisons between the treatments for 
single measurements was carried out using independent 
(unpaired) t tests. Changes in saliva and blood variables 
during the study were analyzed using a two-factor 
(Treatment × Time) between–within-subjects ANOVA 
with repeated measures (time: 0, 8, and 16 weeks of 
intervention). Corresponding assumptions of homoge-
neity of variances and intercorrelation were checked, 
as was sphericity in the data. Any significant F ratios 
subsequently shown were assessed using Student’s paired 
t tests with Holm–Bonferroni correction for multiple 
comparisons applied to the unadjusted p value. Statistical 
significance was accepted at p < .05. Data are expressed 
as M ± SD.
Results
Adherence to the Study
Of the 66 subjects, 56 successfully completed 8 weeks 
of the study, and 54 subjects completed the full 16 weeks 
of the study. Several subjects withdrew due to injury, 
persistent nonrespiratory illness (preventing them from 
performing training), or undisclosed reasons. Adherence 
to the intervention was good; subjects who completed the 
study reported that they had missed taking the supplement 
on average only on 4 days (range 0–13 days). Saliva and 
blood samples were obtained on all three visits from 53 
and 48 subjects, respectively. Subjects were asked at the 
238  Gleeson et al.
end of the study which treatment they thought they had 
taken. Sixty percent said they did not know, 23% thought 
they were on PRO, and 17% thought they were on PLA. 
Of the subjects who expressed an opinion, 43% were 
correct in their selection of treatment and 57% were 
incorrect; hence, the study blinding was effective.
On PRO the baseline characteristics of the subjects 
(n = 27) who completed the study were as follows: age 
25 ± 5 years, body mass 74.3 ± 14.9 kg, height 175 ± 10 
cm, body-mass index 24.2 ± 3.4 kg/m2, and self-reported 
weekly training load 9.1 ± 4.2 hr/week. On PLA the 
baseline characteristics of the subjects (n = 27) were as 
follows: age 24 ± 4 years, body mass 69.4 ± 11.6 kg, 
height 173 ± 9 cm, body-mass index 23.2 ± 2.7 kg/m2, 
and self-reported weekly training load 8.7 ± 3.8 hr/week. 
There were no statistically significant differences between 
the two treatment groups.
Training Loads
Analysis of the IPAQ questionnaires indicated that the 
weekly training loads were relatively stable between and 
within experimental groups over the 16 weeks of the 
study (Figure 1) and that the means were not significantly 
different for the PRO and PLA groups: 67.8 ± 23.2 and 
60.8 ± 20.1 MET-hr/week, respectively (p = .285). This 
is equivalent to about 10 hr of moderate to vigorous 
activity per week.
Infection Symptom Incidence
Analysis of the URTI symptom questionnaires indicated 
that 10% ± 4% of the cohort experienced a URTI episode 
each week. Twenty-four subjects did not experience a 
single URTI episode during the study period, and 29 
experienced at least one. The proportion of subjects 
on PRO who experienced 1 or more weeks with URTI 
symptoms was not significantly different from that on 
PLA (PRO .58, PLA 0.59; p = .947). The number of URTI 
episodes was similar in the two groups (PRO 1.5 ± 2.3, 
PLA 1.4 ± 1.5; p = .710). During weeks when a URTI 
episode was present, the proportion of subjects who took 
medication was similar in the PRO and PLA groups (.55 
and .53, respectively), and the proportion who went to 
see their doctor was small and not significantly different 
in the PRO and PLA groups (.11 and .24, respectively; 
chi-square test statistic = .949, p = .330).
Saliva Antimicrobial Proteins
There were no significant time, treatment, or interaction 
effects for saliva IgA concentration or secretion rate. 
There was a significant main effect of time for saliva 
lysozyme concentration (and secretion rate), with values 
at 16 weeks lower than at baseline, but there was no effect 
of treatment on this (Table 1).
Blood Leukocyte Counts  
and Lymphocyte Subsets
There were no significant time, treatment, or interaction 
effects for blood counts of total leukocytes, neutrophils, 
and monocytes. For blood lymphocyte counts, there was 
significant main effect of time, with values higher after 16 
weeks than at baseline, and a significant effect of treat-
ment, with counts higher on PRO than on PLA (Table 
2). However, the magnitude of the difference in mean 
lymphocyte counts between the PRO and PLA groups 
was not different at baseline, 8 weeks, or 16 weeks.
There were no significant time, treatment, or interac-
tion effects for percentages of T cells (CD3+), T-cytotoxic 
cells (CD3+CD8+), or NK cells (CD3-CD56+), although 
the interaction effect for NK cells was close to signifi-
Figure 1 — Training loads in MET-hr/week over the 16-week study period for subjects who completed the study, M ± SD. No 
statistically significant difference between treatments.
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cance (p = .068), with decreases over time in the PLA 
group and increases over time in the PRO group (Table 
3). There was a significant effect of time for T-helper 
cells (CD3+CD4+), with values higher after 8 weeks 
than at baseline. There was a significant main effect of 
treatment for B cells (CD3-CD19+), with values higher 
on PRO than PLA, but it seems that this is likely to be a 
chance difference that was present at baseline.
The circulating numbers of the different lymphocyte 
subsets were obtained by multiplying the lymphocyte 
count (measured using the Coulter counter) by the per-
centage of the specific subset (measured using the flow 
cytometer). As there were significant time and treatment 
effects for the blood lymphocyte count, it is not surprising 
that likewise there were some significant main effects 
for the various subset counts. These are shown in Table 
4. There were significant main effects of treatment (all 
higher on PRO than PLA) for T cells, T-cytotoxic cells, 
and B cells and increases with time for T-helper cells and 
the T-helper:T-cytotoxic (CD4+/CD8+) ratio. However, 
there were no significant interactions for any of the lym-
phocyte subset counts.
Discussion
The current study investigated the effects of probiotic 
supplementation on self-reported URTI symptoms in 
a group of highly active individuals engaged in their 
normal level of training and competition during the 
months of February to May. The main findings were 
that the proportion of subjects who experienced one or 
more URTI episodes was not significantly different in the 
PRO group than with PLA. During weeks when a URTI 
episode was present, the mean total symptom-severity 
score and duration of symptoms were not different on 
PRO than on PLA. The proportion of subjects who 
took medication when suffering URTI symptoms was 
similar in the PRO and PLA groups, and the difference 
in the proportion who went to see their doctor was small 
and not significantly different between the groups. Saliva 
Table 1 Saliva IgA and Lysozyme Before and After 8 and 16 Weeks of the Intervention, M (SD)
Before 8 weeks 16 weeks p (interaction, time, treatment)
IgA, mg/L
 placebo, n = 27 138 (81) 143 (95) 128 (58) .797, .381, .625
 probiotic, n = 27 135 (90) 127 (101) 123 (62)
IgA secretion rate, μg/min
 placebo 65 (55) 63 (41) 59 (32) .763, .552, .568
 probiotic 58 (57) 63 (36) 57 (29)
Lysozyme, mg/L
 placebo 4.7 (3.6) 3.7 (2.3) 3.6 (2.5) .700, .027a, .560
 probiotic 4.4 (3.8) 3.7 (2.4) 2.9 (2.6)
Lysozyme secretion rate, μg/min
 placebo 2.3 (2.4) 1.6 (1.1) 1.7 (1.3) .533, .029b, .604
 probiotic 2.1 (2.5) 1.7 (1.1) 1.3 (1.3)
aBefore > 16 weeks, p = .021. bBefore > 16 weeks, p = .022.
Table 2 Total and Differential Leukocyte Counts (Cells × 109/L) Before and After 8 and 16 Weeks  
of the Intervention, M (SD)
Before 8 weeks 16 weeks p (interaction, time, treatment)
Leukocytes
 placebo, n = 25 5.50 (1.35) 5.52 (1.47) 5.60 (1.21) .970, .460, .802
 probiotic, n = 22 5.56 (1.24) 5.57 (1.28) 5.77 (1.04)
Neutrophils
 placebo 2.96 (1.11) 2.97 (1.14) 2.87 (0.80) .883, .997, .119
 probiotic 2.59 (0.76) 2.57 (0.77) 2.65 (0.83)
Monocytes
 placebo 0.48 (0.11) 0.47 (0.15) 0.49 (0.15) .797, .748, .651
 probiotic 0.48 (0.13) 0.50 (0.19) 0.50 (0.13)
Lymphocytes 
 placebo 1.84 (0.42) 1.87 (0.52) 1.99 (0.46) .957, .013a, .014a,b
 probiotic 2.18 (0.54) 2.22 (0.66) 2.36 (0.61)
aBefore > 16 weeks, p = .010. bProbiotic > placebo.
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lysozyme concentration fell over time, but the magnitude 
of change was not different on PRO compared with PLA. 
It is not clear why the saliva lysozyme concentration was 
lower at the end of the study; it could be a seasonal effect 
or due to an accumulation of training stress.
Other than a main effect of treatment for blood 
lymphocyte counts (higher on PRO than PLA) and some 
lymphocyte subsets (T cells, T-cytotoxic cells, and B 
cells), there were no differences in any of the immune 
variables measured for PRO compared with PLA at Week 
0 (baseline) or after 8 or 16 weeks of intervention. The 
lack of positive clinical consequences does not provide 
evidence for any beneficial effect of daily L. salivarius 
ingestion in a cohort of highly physically active people. 
This is in contrast to several recent studies that have 
reported beneficial effects of other Lactobacillus probi-
Table 3  Percentages of Total Lymphocytes Before and After 8 and 16 Weeks of the Intervention,  
M (SD)
Before 8 weeks 16 weeks p (interaction, time, treatment)
T cells CD3+ 
 placebo, n = 25 60.2 (9.5) 61.9 (8.7) 60.4 (9.7) .143, .596, .754
 probiotic, n = 20 60.1 (10.0) 60.6 (6.2) 63.7 (5.9)
T-helper cells CD3+CD4+ 
 placebo 34.1 (6.3) 36.4 (7.1) 35.4 (7.6) .548, .016a, .380
 probiotic 31.7 (7.7) 34.0 (8.6) 34.8 (7.5)
T-cytotoxic cells CD3+CD8+ 
 placebo 23.6 (5.9) 23.5 (5.4) 23.0 (5.3) .204, .757, .414
 probiotic 24.3 (8.0) 24.4 (7.4) 25.0 (6.7)
B cells CD3-CD19+ 
 placebo 8.9 (3.0) 8.8 (3.1) 8.6 (3.2) .942, .524, .042b
 probiotic 11.2 (4.9) 11.0 (4.0) 10.7 (4.1)
Natural killer cells CD3-CD56+ 
 placebo 11.4 (5.8) 11.0 (5.7) 10.4 (5.4) .068, .802, .811
 probiotic 10.0 (4.9) 10.2 (4.8) 11.6 (4.8)
aBefore > 8 weeks, p = .012. bProbiotic > placebo, p = .093.
Table 4 Lymphocyte Counts (Cells × 109/L) Before and After 8 and 16 Weeks of the Intervention,  
M (SD)
Before 8 weeks 16 weeks p (interaction, time, treatment)
T cells CD3+
 placebo, n = 20 1.09 (0.32) 1.14 (0.36) 1.17 (0.29) .446, .120, .018a
 probiotic, n = 25 1.35 (0.46) 1.31 (0.41) 1.45 (0.39)
T-helper cells CD3+CD4+
 placebo 0.61 (0.18) 0.66 (0.22) 0.68 (0.19) .714, .045b, .153
 probiotic 0.70 (0.25) 0.71 (0.21) 0.78 (0.20)
T-cytotoxic CD3+CD8+
 placebo 0.43 (0.15) 0.43 (0.16) 0.45 (0.14) .453, .170, .037c
 probiotic 0.57 (0.31) 0.54 (0.27) 0.60 (0.28)
B cells CD3-CD19+d
 placebo 0.16 (0.07) 0.16 (0.07) 0.17 (0.07) .562, .508, .010
 probiotic 0.26 (0.16) 0.24 (0.12) 0.25 (0.17)
Natural killer cells CD3-CD56+
 placebo 0.21 (0.12) 0.20 (0.12) 0.20 (0.11) .620, .134, .415
 probiotic 0.21 (0.10) 0.22 (0.11) 0.26 (0.12)
CD4+:CD8+ ratio
 placebo 1.53 (0.46) 1.63 (0.50) 1.62 (0.49) .462, .003e, .636
 probiotic 1.46 (0.62) 1.58 (0.81) 1.49 (0.64)
aProbiotic > placebo, p = .124. bBefore > 16 weeks, p = .037. cProbiotic > placebo, p = .098. dProbiotic > placebo, p = .143. eBefore > 8 weeks, 
p = .003; before > 16 weeks, p = .038.
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otics on URTI incidence and some aspects of immune 
function in endurance athletes. For example, Cox et al. 
(2010) observed fewer days of respiratory illness and 
lower severity of respiratory illness in subjects taking 
a daily Lactobacillus probiotic, which was attributed to 
higher spontaneous IFN-γ production (Cox et al., 2010). 
Others have reported lower URTI incidence (Gleeson et 
al., 2011; West et al., 2011) and improved maintenance 
of salivary IgA levels (Gleeson et al., 2011a; Tiollier et 
al., 2007) with Lactobacillus probiotics during periods 
of physical stress. The dose of probiotic used in the cur-
rent study was similar to that of the other studies cited 
here, although it was administered as a soluble powder 
rather than as part of a fermented dairy product; however, 
this should not have influenced its efficacy because the 
manufacturer carried out tests to confirm the bacterial 
viability of the supplied probiotic product.
Several factors may have confounded the lack of 
impact of the probiotic supplement on infection out-
comes: 
•	 The	mean	weekly	 physical	 activity	 levels	 esti-
mated from the IPAQ questionnaires indicated that 
training loads were on average about 10% higher 
for subjects in the PRO group than in the PLA 
group, although this difference was not statistically 
significant. 
•	 The	blood	lymphocyte,	T	cell,	T-cytotoxic	cell,	and	
B cell counts were significantly higher at baseline 
in the PRO group. The subjects were randomly allo-
cated to the two treatments, with stratification only 
for gender, so these differences in cell counts arose 
purely by chance. 
•	 Most	subjects	were	female,	and	West	et	al.	(2011)	
have reported that L. fermentum probiotic supple-
mentation in a cohort of 64 male and 35 female 
elite endurance athletes was associated with a lower 
symptom load for chest infections and less use of 
cold and flu medications in males taking the probiotic 
compared with placebo but that differences in clini-
cal outcomes for females between the two groups 
were not evident. 
•	 URTI	 incidence	was	not	 as	 high	 as	 expected;	 the	
study began in February and therefore missed the 
winter months when URTI incidence is generally 
highest in the UK. 
•	 The	number	of	subjects	may	not	have	been	sufficient,	
and the study was underpowered to detect any small 
differences in URTI incidence. 
•	 As	effects	of	probiotics	are	known	to	be	strain	spe-
cific, it may be that the strain used in this study was 
just not effective.
Minocha (2009) cautions that results from meta-
analyses and systematic reviews that combine results of 
studies from different types of probiotics to examine the 
effects in any disease state should be interpreted with 
caution. Specific strains are effective in specific disease 
states, and different probiotic strains vary in their ability 
to modulate the immune system (Gill & Prasad, 2008). 
No two probiotics are exactly alike, so we should not 
expect reproducible results from studies that employ 
different species or strains, variable formulations, and 
diverse dosing schedules. Therefore, the efficacy of 
each strain needs to be carefully demonstrated through 
rigorously designed (randomized, double-blind, placebo-
controlled) studies.
In the general population, several recent large-scale 
human studies have demonstrated that regular, long-
term intake of various probiotic-prebiotic combinations 
improved health by reducing both the incidence and the 
severity of respiratory diseases during the winter season 
(Pregliasco et al., 2008; Winkler, de Vrese, Laue, & 
Schrezenmeir, 2005). Other studies have reported that 
probiotics are associated with shortening of common cold 
symptoms and reduced severity of symptoms without 
an effect on infection incidence in adults during spring 
periods (de Vrese et al., 2006; Guillemard, Tondu, Lacoin, 
& Schrezenmeir, 2010).
We conclude that regular ingestion of L. salivarius 
does not appear to be beneficial in reducing the frequency 
of URTI in a predominantly female athletic cohort and 
does not affect levels of salivary antimicrobial proteins 
or blood leukocyte and lymphocyte subset counts during 
a spring period of training and competition.
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